Compare Alcon AG (ALC) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Oatly Group AB - ADR — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Oatly Group AB - ADR trades at $9.38 (market cap $301.32M). The key difference: Alcon AG is far larger — about 108.5× Oatly Group AB - ADR's market cap, and Alcon AG pays a 0.54% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| ALC | OTLY | |
|---|---|---|
Market Cap | $32.69B | $301.32M |
Sector | Health | Consumer Staples |
52-Week High | $92.22 | $18.54 |
52-Week Low | $62.02 | $8.03 |
Enterprise Value | $36.28B | $798.94M |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
OTLY trades at $9.65, down 3.02% today, with a bullish technical signal from moving averages and ADX indicators. Revenue grew to $862.46M in 2025, but the company reported a net loss of $152.77M, with negative cash flow and high debt levels. Recent news includes a partnership with Nespresso and upcoming Q2 2026 earnings on July 22, 2026.
The outlook remains challenging due to persistent losses and cash burn, though revenue growth and a strong brand offer potential. Key risks include high leverage and competitive pressures. Analysts are divided, with 44% buy ratings but 50% hold, reflecting cautious optimism amid financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
